Compare · BBLG vs SNN
BBLG vs SNN
Side-by-side comparison of Bone Biologics Corp (BBLG) and Smith & Nephew SNATS Inc. (SNN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BBLG and SNN operate in Industrial Specialties (Health Care), so they compete in similar markets.
- SNN is the larger of the two at $12.99B, about 6704.9x BBLG ($1.9M).
- Both names hit the wire about 10 times in the past 4 weeks.
- SNN has more recent analyst coverage (23 ratings vs 0 for BBLG).
- Company
- Bone Biologics Corp
- Smith & Nephew SNATS Inc.
- Price
- -
- -
- Market cap
- $1.9M
- $12.99B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 10
- 10
- Recent ratings
- 0
- 23
Bone Biologics Corp
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Smith & Nephew SNATS Inc.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest BBLG
- SEC Form 424B3 filed by Bone Biologics Corp
- Bone Biologics Corp filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
- SEC Form DEFA14A filed by Bone Biologics Corp
- SEC Form S-3 filed by Bone Biologics Corp
- Bone Biologics Corp filed SEC Form 8-K: Other Events
- Bone Biologics Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form DEFA14A filed by Bone Biologics Corp
- SEC Form DEF 14A filed by Bone Biologics Corp
Latest SNN
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- Smith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons
- New German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisions
- New German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complications
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.
- SEC Form 6-K filed by Smith & Nephew SNATS Inc.